SCHEMBL16655007

SCHEMBL16655007

Nc1ccc(C(=O)N2CCC(Nc3ncc(Cl)c(-c4cn(S(=O)(=O)c5ccccc5)c5ccccc45)n3)CC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 13/20 0.46
MAPK8 P45983 11/20 0.46
MAPK9 P45984 11/20 0.46
JUN P05412 10/20 0.46
MAPK10 P53779 7/20 0.46
CDK7 P50613 6/20 0.46
CCNT1 O60563 2/20 0.46
CDK9 P50750 2/20 0.46
CCNH P51946 2/20 0.46
MNAT1 P51948 1/20 0.46
CCNA2 P20248 3/20 0.44
CCNA1 P78396 2/20 0.44
CCNK O75909 1/20 0.43
CDK13 Q14004 1/20 0.43
CDK12 Q9NYV4 1/20 0.43
HTR6 P50406 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16654808 0.95 CDK2 (0.48) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL16655415 0.95 CDK2 (0.48) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL16654810 0.95 CDK2 (0.48) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL18045081 0.92 CDK7 (0.48) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL16655056 0.92 CDK7 (0.48) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL16655351 0.91 MAPK8 (0.45) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL16655134 0.91 CDK7 (0.48) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL16655016 0.90 MAPK8 (0.46) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL18047389 0.89 CDK7 (0.46) CDK2MAPK8MAPK9JUNMAPK10
SCHEMBL18047388 0.89 CDK7 (0.46) CDK2MAPK8MAPK9JUNMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190292167-A1 HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2019-09-26 US disclosed
US-20190292167-A1 HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2019-09-26 US disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES SYROS PHARMACEUTICALS INC (US) 2016-09-15 US disclosed
EP-3057954-A2 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Syros Pharmaceuticals, Inc. (US) 2016-08-24 EP disclosed
WO-2015058163-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-04-23 WO disclosed
WO-2015058163-A2 INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) SYROS PHARMACEUTICALS, INC. (US) 2015-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190292167-A1 HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES CDK7, CDK3, CDK17 CDK2 9/4885MAPK8 352/4885MAPK9 506/4885
US-20160264552-A1 HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES CDK7, CDK6, CDK3 CDK2 4/4885MAPK8 532/4885MAPK9 599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.